Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 787.37

+3.4%

Nov 25 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	12/4/2015 2:19:36 PM
	Read Replies (1) of 3559

From the Forbes (http://www.forbes.com/sites/johnlamattina/2015/12/04/for-hepatitis-c-drugs-u-s-prices-are-cheaper-than-in-europe/): Furthermore, Miller boasted that Express EXPR +3.14% Scripts pays far less for the new cholesterol lowering PCSK-9 drugs like Regeneron’s Praluent, than the sticker price of $9,400/patient/year. and The same scenario played out for the PCSK-9 pricing discussions that Dr. Miller had with Regeneron. Given the choice between Praluent and Amgen’s Repatha, Express Scripts opted for the former. While he didn’t say what Express Scripts was actually paying for Praluent, Dr. Len Schleifer, CEO of Regeneron, glumly told the Forbes Healthcare Summit audience, “Dr. Miller drives a hard bargain.” It is undoubtedly far less than the $9,400 initially advertised. Furthermore, the bargaining position of payers will be even more enhanced should Pfizer’s PCSK-9 inhibitor, which is in late-stage development, make it to market. Pfizer will likely need to make discounts for its drug given the entrenched positions of Praluent and Repatha. Did author "mixed" things/story here???

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next